0
Special Feature |

Image of the Month—Diagnosis FREE

[+] Author Affiliations

SECTION EDITOR: CARL E. BREDENBERG, MD

More Author Information
JAMA Surg. 2013;148(2):204. doi:10.1001/archsurg.148.2.204.
Text Size: A A A
Published online

The fludeoxyglucose F18–positron emission tomographic/CT scan (Figure 1) shows increased uptake involving most of the upper half of the sternal body. Her α1-fetoprotein level was 943 ng/mL, and she underwent a fine-needle aspiration and a core biopsy of the sternal mass (Figure 2A). The fine-needle aspiration revealed a malignant neoplasm composed of loose clusters of large polygonal cells with a moderate amount of cytoplasm (Figure 2B and C). A core biopsy showed the tumor to be arranged in clusters with surrounding endothelial cells. Immunohistochemistry performed on the core biopsy demonstrated tumor cell immunoreactivity for α1-fetoprotein and hepatocyte paraffin 1, which is diagnostic for metastatic HCC.

Place holder to copy figure label and caption
Graphic Jump Location

Figure 1. A and B, Fludeoxyglucose F18–positron emission tomographic/computed tomographic scans showing increased uptake in the upper half of the sternal body. L indicates left; and R, right.

Place holder to copy figure label and caption
Graphic Jump Location

Figure 2. Fine-needle aspiration and core biopsy of sternal mass (A) using Papanicolaou stain (B [original magnification ×400]) and hematoxylin-eosin (C [original magnification ×100]).

Recurrence of HCC after LT is rare in the appropriately selected patient. The largest series reported an overall recurrence rate of 11% to 18%.1,2 Patients whose explant tumor characteristics are within the Milan criteria have a recurrence rate after LT of 8%. Those with characteristics outside the criteria have a 50% to 60% incidence of recurrence 4 years after LT.3 A series of 57 patients with HCC recurrence after LT showed that 52% of these patients had extrahepatic recurrence, 16% had recurrence limited to the liver, and 31% presented both hepatic and extrahepatic recurrences.1

The prognostic factors that increase the risk of posttransplant recurrence were vascular invasion, poorly differentiated HCC, a tumor size of greater than 5 cm, and HCC exceeding the Milan criteria.4 The recurrence of HCC after LT results in significantly diminished survival.1 If a posttransplant recurrence is detected, surgical intervention is reserved for patients with localized and resectable HCCs, no matter where the tumor is localized. This decision is based on the fact that those patients whose lesions can be removed fare better than those with unresectable recurrence.5 Yet, the cumulative experience is too small to draw firm conclusions regarding clinical decisions in management and prognostic factors affecting surgical resection of recurrences.6

Our patient had a tumor that met the Milan criteria. Her explant showed a moderately differentiated lesion, 2.5 cm in maximal diameter and limited to 1 lobe without vascular invasion. She also had no preoperative evidence of bone metastases. Nevertheless, a recurrence on the sternum was detected 11 months after LT. She underwent resection of the osteolytic sternal lesion with coverage by pectoral muscle flaps. Postoperatively, she received sirolimus and sorafenib. Sirolimus has been shown to exert beneficial effects on recurrence-free survival.7,8 Some cases have been reported in which a combination of sorafenib and sirolimus showed a significant improvement in patients with HCC recurrence.9,10 However, to our knowledge, the role of sirolimus and sorafenib as adjunct therapy to resection for HCC recurrence has not been conclusively studied yet.

Return to Quiz Case.

Correspondence: Jorge Ortiz, MD, Department of Transplant Surgery, Albert Einstein Healthcare Network, Klein Professional Bldg, 5401 Old York Rd, Ste 505, Philadelphia, PA 19141(ortizjor@einstein.edu).

Accepted for Publication: December 23, 2011.

Author Contributions:Study concept and design: Chavez, Danniel, and Ortiz. Acquisition of data: Chavez, Danniel, Jarrar, Khanmoradi, and Ortiz. Analysis and interpretation of data: Danniel, Miick, Khanmoradi, and Ortiz. Drafting of the manuscript: Chavez, Danniel, Miick, Jarrar, and Ortiz. Critical revision of the manuscript for important intellectual content: Miick, Khanmoradi, and Ortiz. Statistical analysis: Danniel. Obtained funding: Chavez. Administrative, technical, and material support: Chavez, Danniel, Miick, and Jarrar. Study supervision: Khanmoradi and Ortiz.

Conflict of Interest Disclosures: None reported.

Roayaie S, Schwartz JD, Sung MW,  et al.  Recurrence of hepatocellular carcinoma after liver transplant.  Liver Transpl. 2004;10(4):534-540
PubMed   |  Link to Article
Regalia E, Fassati LR, Valente U,  et al.  Pattern and management of recurrent hepatocellular carcinoma after liver transplantation.  J Hepatobiliary Pancreat Surg. 1998;5(1):29-34
PubMed   |  Link to Article
Roberts JP. Tumor surveillance-what can and should be done?  Liver Transpl. 2005;11(11):(suppl 2)  S45-S46
PubMed   |  Link to Article
Sotiropoulos GC, Molmenti EP, Lösch C, Beckebaum S, Broelsch CE, Lang H. Meta-analysis of tumor recurrence after liver transplantation for hepatocellular carcinoma based on 1,198 cases.  Eur J Med Res. 2007;12(10):527-534
PubMed
Taketomi A, Fukuhara T, Morita K,  et al.  Improved results of a surgical resection for the recurrence of hepatocellular carcinoma after living donor liver transplantation.  Ann Surg Oncol. 2010;17(9):2283-2289
PubMed   |  Link to Article
Zimmerman MA, Ghobrial RM, Tong MJ,  et al.  Recurrence of hepatocellular carcinoma following liver transplantation.  Arch Surg. 2008;143(2):182-188, discussion 188
PubMed   |  Link to Article
Chinnakotla S, Davis GL, Vasani S,  et al.  Impact of sirolimus on the recurrence of hepatocellular carcinoma after liver transplantation.  Liver Transpl. 2009;15(12):1834-1842
PubMed   |  Link to Article
Kornberg A, Küpper B, Tannapfel A,  et al.  Long-term survival after recurrent hepatocellular carcinoma in liver transplant patients.  Eur J Surg Oncol. 2010;36(3):275-280
PubMed   |  Link to Article
Llovet JM, Ricci S, Mazzaferro V,  et al; SHARP Investigators Study Group.  Sorafenib in advanced hepatocellular carcinoma.  N Engl J Med. 2008;359(4):378-390
PubMed   |  Link to Article
Wang Y, Speeg KV, Washburn WK, Halff G. Sirolimus plus sorafenib in treating HCC recurrence after liver transplantation.  World J Gastroenterol. 2010;16(43):5518-5522
PubMed   |  Link to Article

Figures

Place holder to copy figure label and caption
Graphic Jump Location

Figure 1. A and B, Fludeoxyglucose F18–positron emission tomographic/computed tomographic scans showing increased uptake in the upper half of the sternal body. L indicates left; and R, right.

Place holder to copy figure label and caption
Graphic Jump Location

Figure 2. Fine-needle aspiration and core biopsy of sternal mass (A) using Papanicolaou stain (B [original magnification ×400]) and hematoxylin-eosin (C [original magnification ×100]).

Tables

References

Roayaie S, Schwartz JD, Sung MW,  et al.  Recurrence of hepatocellular carcinoma after liver transplant.  Liver Transpl. 2004;10(4):534-540
PubMed   |  Link to Article
Regalia E, Fassati LR, Valente U,  et al.  Pattern and management of recurrent hepatocellular carcinoma after liver transplantation.  J Hepatobiliary Pancreat Surg. 1998;5(1):29-34
PubMed   |  Link to Article
Roberts JP. Tumor surveillance-what can and should be done?  Liver Transpl. 2005;11(11):(suppl 2)  S45-S46
PubMed   |  Link to Article
Sotiropoulos GC, Molmenti EP, Lösch C, Beckebaum S, Broelsch CE, Lang H. Meta-analysis of tumor recurrence after liver transplantation for hepatocellular carcinoma based on 1,198 cases.  Eur J Med Res. 2007;12(10):527-534
PubMed
Taketomi A, Fukuhara T, Morita K,  et al.  Improved results of a surgical resection for the recurrence of hepatocellular carcinoma after living donor liver transplantation.  Ann Surg Oncol. 2010;17(9):2283-2289
PubMed   |  Link to Article
Zimmerman MA, Ghobrial RM, Tong MJ,  et al.  Recurrence of hepatocellular carcinoma following liver transplantation.  Arch Surg. 2008;143(2):182-188, discussion 188
PubMed   |  Link to Article
Chinnakotla S, Davis GL, Vasani S,  et al.  Impact of sirolimus on the recurrence of hepatocellular carcinoma after liver transplantation.  Liver Transpl. 2009;15(12):1834-1842
PubMed   |  Link to Article
Kornberg A, Küpper B, Tannapfel A,  et al.  Long-term survival after recurrent hepatocellular carcinoma in liver transplant patients.  Eur J Surg Oncol. 2010;36(3):275-280
PubMed   |  Link to Article
Llovet JM, Ricci S, Mazzaferro V,  et al; SHARP Investigators Study Group.  Sorafenib in advanced hepatocellular carcinoma.  N Engl J Med. 2008;359(4):378-390
PubMed   |  Link to Article
Wang Y, Speeg KV, Washburn WK, Halff G. Sirolimus plus sorafenib in treating HCC recurrence after liver transplantation.  World J Gastroenterol. 2010;16(43):5518-5522
PubMed   |  Link to Article

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics